Pellegata N S, Dieguez-Lucena J L, Joensuu T, Lau S, Montgomery K T, Krahe R, Kivelä T, Kucherlapati R, Forsius H, de la Chapelle A
Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
Nat Genet. 2000 May;25(1):91-5. doi: 10.1038/75664.
Specialized collagens and small leucine-rich proteoglycans (SLRPs) interact to produce the transparent corneal structure. In cornea plana, the forward convex curvature is flattened, leading to a decrease in refraction. A more severe, recessively inherited form (CNA2; MIM 217300) and a milder, dominantly inherited form (CNA1; MIM 121400) exist. CNA2 is a rare disorder with a worldwide distribution, but a high prevalence in the Finnish population. The gene mutated in CNA2 was assigned by linkage analysis to 12q (refs 4, 5), where there is a cluster of several SLRP genes. We cloned two additional SLRP genes highly expressed in cornea: KERA (encoding keratocan) in 12q and OGN (encoding osteoglycin) in 9q. Here we report mutations in KERA in 47 CNA2 patients: 46 Finnish patients are homozygous for a founder missense mutation, leading to the substitution of a highly conserved amino acid; and one American patient is homozygous for a mutation leading to a premature stop codon that truncates the KERA protein. Our data establish that mutations in KERA cause CNA2. CNA1 patients had no mutations in these proteoglycan genes.
特殊的胶原蛋白和富含亮氨酸的小分子蛋白聚糖(SLRPs)相互作用,形成透明的角膜结构。在扁平角膜中,向前凸出的曲率变平,导致屈光能力下降。存在一种较为严重的隐性遗传形式(CNA2;MIM 217300)和一种较为温和的显性遗传形式(CNA1;MIM 121400)。CNA2是一种罕见疾病,在全球范围内均有分布,但在芬兰人群中患病率较高。通过连锁分析将CNA2中发生突变的基因定位到12号染色体长臂(参考文献4、5),该区域存在几个SLRP基因簇。我们克隆了另外两个在角膜中高表达的SLRP基因:位于12号染色体长臂的KERA(编码角膜蛋白聚糖)和位于9号染色体的OGN(编码骨形成蛋白聚糖)。在此我们报告47例CNA2患者的KERA基因发生突变:46例芬兰患者对于一个始祖错义突变呈纯合状态,该突变导致一个高度保守的氨基酸被替换;1例美国患者对于一个导致KERA蛋白截短的提前终止密码子突变呈纯合状态。我们的数据证实KERA基因的突变会导致CNA2。CNA1患者在这些蛋白聚糖基因中未发生突变。